Jeisys Medical Inc.

As of June 30, 2024, Jeisys Medical Inc. has 75.43M shares outstanding.

As of June 30, 2024, Jeisys Medical Inc. trades at a trailing price-to-earnings ratio of 35.09.

As of June 30, 2024, Jeisys Medical Inc. trades at an EV/EBITDA multiple of 16.54 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 5.86 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 16.54 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. Jeisys Medical Inc. trades at an EV/FCF ratio of 25.82, comparing the total takeover cost of the business to the cash it actually generates for all capital providers.

As of June 30, 2024, Jeisys Medical Inc. maintains a current ratio of 2.00, meaning it holds 2.0x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2024, Jeisys Medical Inc. posted a return on equity (ROE) of 102.61, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 38.91 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 16.53, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 76.41, useful for judging operating efficiency across full business cycles. Inventory turnover of 4.71 indicates how many times Jeisys Medical Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

These figures cover the twelve months ended June 30, 2024. That works out to an effective tax rate of 25.72, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items.

As of the close on October 18, 2024, Jeisys Medical Inc.'s stock has gained approximately 22.86% over the past 52 weeks. The 50-day moving average sits at 12,881.60, while the 200-day moving average is 11,054.10.

Over the twelve months ended June 30, 2024, Jeisys Medical Inc. posted a gross margin of 69.78, reflecting its pricing power and cost economics. The operating margin of 35.41 and net profit margin of 16.67 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2024. Free cash flow yield stands at 3.82, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield is negative at -3.59, meaning Jeisys Medical Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of June 30, 2024, Jeisys Medical Inc. has an Altman Z-Score of 8.56, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.